Literature DB >> 10606841

Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists.

A Fourrier1, I Gasquet, M P Allicar, M Bouhassira, J P Lépine, B Bégaud.   

Abstract

AIMS: To describe the psychiatric indications of neuroleptics (especially the relative share of schizophrenic and other psychotic disorders) and the usage patterns of these drugs (dose, duration, coprescriptions).
METHODS: A one-day national cross-sectional survey in a random sample of 723 French psychiatrists was carried out in 1996. Each psychiatrist was asked to complete a standardized questionnaire for the first three patients seen the day of the survey to whom at least one neuroleptic was prescribed (initiated or renewed).
RESULTS: One thousand seven hundred and fifty-four questionnaires were returned. Three quarters of the patients (74%) were psychotic (664 with schizophrenia, and 636 other psychosis), 19. 3% were depressive and 6.7% had other psychiatric disorders. Phenothiazines were the most often prescribed (40.8%), followed by butyrophenones (22.5%), benzamides (15.8%), other neuroleptics (14. 8%) and thioxanthenes (6.1%). Among schizophrenic subjects, an average number of 1.54 (95% CI: 1.50-1.60) neuroleptics were prescribed per patient, compared with 1.4 (95% CI: 1.32-1.41) and 1. 2 (95% CI: 1.14-1.23) in other psychotic and depressive subjects, respectively. Regardless of the indication, non-neuroleptic psychotropic drugs were coprescribed in 75.4%, mainly benzodiazepines (75.7%). Adjuvant drugs used in prevention or treatment of side-effects were coprescribed in 46.7%, mostly anticholinergic antiparkinsonians (86.1%).
CONCLUSIONS: Neuroleptics are mainly prescribed for psychotic disorders and especially schizophrenia. However, current recommendations are not always followed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10606841      PMCID: PMC2014886          DOI: 10.1046/j.1365-2125.2000.00108.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

Review 1.  [The consumption of psychotropics in France and some european countries].

Authors:  M Legrain; T Lecomte
Journal:  Ann Pharm Fr       Date:  1998

2.  Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.

Authors:  R A Kiivet; A Llerena; M L Dahl; L Rootslane; J Sánchez Vega; T Eklundh; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

Review 3.  Chronic neuroleptic use in manic-depressive illness.

Authors:  M J Sernyak; S W Woods
Journal:  Psychopharmacol Bull       Date:  1993

4.  Utilization of neuroleptic drugs in Italian mental health services: a survey in Piedmont.

Authors:  G Tibaldi; C Munizza; P Bollini; E Pirfo; F Punzo; F Gramaglia
Journal:  Psychiatr Serv       Date:  1997-02       Impact factor: 3.084

5.  Pattern of therapeutic intervention and role of psychiatric settings: a survey in two regions of Italy.

Authors:  G Muscettola; M Casiello; P Bolline; G Sebastiani; S Pampallona; G Tognoni
Journal:  Acta Psychiatr Scand       Date:  1987-01       Impact factor: 6.392

  5 in total
  17 in total

1.  Psychotropic combination in schizophrenia.

Authors:  E Acquaviva; I Gasquet; B Falissard
Journal:  Eur J Clin Pharmacol       Date:  2005-11-08       Impact factor: 2.953

2.  Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

Authors:  Christoph U Correll; Anne M Frederickson; John M Kane; Peter Manu
Journal:  Schizophr Res       Date:  2006-10-27       Impact factor: 4.939

Review 3.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

4.  Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior.

Authors:  Christoph U Correll; Ladan Shaikh; Juan A Gallego; Jeffrey Nachbar; Vladimir Olshanskiy; Taishiro Kishimoto; John M Kane
Journal:  Schizophr Res       Date:  2011-03-21       Impact factor: 4.939

5.  Patterns and correlates of benzodiazepine use in the French general population.

Authors:  Rajaa Lagnaoui; Fanny Depont; Annie Fourrier; Abdelillah Abouelfath; Bernard Bégaud; Hélène Verdoux; Nicholas Moore
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

Review 6.  The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders.

Authors:  Baptiste Pignon; Chloé Tezenas du Montcel; Louise Carton; Antoine Pelissolo
Journal:  Curr Psychiatry Rep       Date:  2017-11-07       Impact factor: 5.285

7.  Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey.

Authors:  Lorenza Magliano; Andrea Fiorillo; Manuela Guarneri; Cecilia Marasco; Corrado De Rosa; Claudio Malangone; Mario Maj
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

Review 8.  Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment.

Authors:  Nitin Toteja; Juan A Gallego; Ema Saito; Tobias Gerhard; Almut Winterstein; Mark Olfson; Christoph U Correll
Journal:  Int J Neuropsychopharmacol       Date:  2013-05-14       Impact factor: 5.176

9.  Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.

Authors:  Taishiro Kishimoto; Koichiro Watanabe; Hiroyuki Uchida; Masaru Mimura; John M Kane; Christoph U Correll
Journal:  Psychiatry Res       Date:  2013-04-18       Impact factor: 3.222

Review 10.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.